论文部分内容阅读
应用C—erbB—2癌基因蛋白和波形蛋白组(vim)单克隆抗体,免疫组化S—P法,对86例乳腺病(79例癌)进行丁标记分析,结果显示C—erbB—2阳性46例,vim((?)～廾)阳性40例,阳性率分别为58.2％(46/79),50.6％(40/79)。统计分析表明,C—erbB—2表达与肿瘤分级及大小关系不大,而与淋巴结转移关系密切相关(p<0.05)。vim表达与肿瘤的分级、大小及淋巴结均呈相关(p<0.05)。对其中54例进行了随访C—erbB—2及vim均阳性者其死亡率(67.6％)显著高于单一阳性者。表明此两种标记物的阳性表达与乳腺癌的预后有关。
C-erbB-2 oncoprotein and vimentin (vim) monoclonal antibody, immunohistochemical S-P method, and D-marker analysis on 86 cases of breast disease (79 cases of cancer) showed C-erbB-2 Positive in 46 cases, vim ((?) ~ 廾) positive in 40 cases, the positive rate were 58.2% (46/79), 50.6% (40/79). Statistical analysis showed that the expression of C-erbB-2 was not related to tumor grade and size, but closely related to lymph node metastasis (p<0.05). The expression of vim was correlated with tumor grade, size and lymph node (p<0.05). The mortality rate (67.6%) of 54 patients who were followed up for C-erbB-2 and vim all positive was significantly higher than that of the single positive. This indicates that the positive expression of these two markers is related to the prognosis of breast cancer.